Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol

INTRODUCTION: The POInT study, an investigator initiated, randomised, placebo-controlled, double-blind, multicentre primary prevention trial is conducted to determine whether daily administration of oral insulin, from age 4.0 months to 7.0 months until age 36.0 months to children with elevated genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegler, Anette-Gabriele, Achenbach, Peter, Berner, Reinhard, Casteels, Kristina, Danne, Thomas, Gündert, Melanie, Hasford, Joerg, Hoffmann, Verena Sophia, Kordonouri, Olga, Lange, Karin, Elding Larsson, Helena, Lundgren, Markus, Snape, Matthew D, Szypowska, Agnieszka, Todd, John A, Bonifacio, Ezio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609035/
https://www.ncbi.nlm.nih.gov/pubmed/31256036
http://dx.doi.org/10.1136/bmjopen-2018-028578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609035/
https://www.ncbi.nlm.nih.gov/pubmed/31256036
http://dx.doi.org/10.1136/bmjopen-2018-028578

Ejemplares similares